In vivo selection of plasmodium falciparum pfcrt and pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 734-737

  Baraka, Vito ^a,b   Tinto, Halidou ^c   Valea, Innocent ^c   Fitzhenry, Robert ^d   Delgado Ratto, Christopher ^b   Mbonye, Martin K ^b,e   Van Overmeir, Chantal ^d   Rosanas Urgell, Anna ^d   Van Geertruyden, Jean Pierre ^b   D'Alessro, Umberto ^d,f,g   Erhartd, Annette ^d  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c CENTRE MURAZ   (Burkina Faso)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^f MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; ARTEMISININ DERIVATIVE; CARRIER PROTEIN; DIHYDROARTEMISININ; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; MDR1 PROTEIN, PLASMODIUM FALCIPARUM; MULTIDRUG RESISTANCE PROTEIN; PFCRT PROTEIN, PLASMODIUM FALCIPARUM; PIPERAQUINE; PROTOZOAL PROTEIN; QUINOLINE DERIVATIVE; TRANQUILIZER;

ARTICLE; BURKINA FASO; CODON; DRUG EFFICACY; FOLLOW UP; GENE; GENE MUTATION; GENETIC VARIABILITY; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; MONOTHERAPY; NONHUMAN; PFCRT GENE; PFMDR1 GENE; PLASMODIUM FALCIPARUM; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT OUTCOME; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; MALARIA, FALCIPARUM;

ANTIMANIC AGENTS; ARTEMISININS; BURKINA FASO; DRUG COMBINATIONS; DRUG RESISTANCE; ETHANOLAMINES; FLUORENES; GENETIC VARIATION; HUMANS; MALARIA, FALCIPARUM; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; QUINOLINES;

EID: 84920115886     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03647-14     Document Type: Article

References (27)

1. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620. http://dx.doi.org/10.1056/NEJMc0805011.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria.NEngl J Med 361:455-467. http: //dx.doi.org/10.1056/NEJMoa0808859.
3. WHO. 2014. Status report on artemisinin resistance. World Health Organization, Geneva, Switzerland.
4. WHO. 2014. Country antimalarial drug policies: by region. World Health Organization, Geneva, Switzerland.
5. nd ed. World Health Organization, Geneva, Switzerland.
6. Davis TME, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. 2005. Piperaquine-A resurgent antimalarial drug. Drugs 65:75-87. http://dx .doi.org/10.2165/00003495-200565010-00004.
7. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344:257-263. http://dx.doi.org/10.1056/NEJ M200101253440403.
8. Tinto H, Guekoun L, Zongo I, Guiguemde RT, D'Alessandro U, Ouedraogo JB. 2008. Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-I Y86) and amodiaquine resistance in Burkina Faso. Trop Med Int Health 13:238-240. http://dx.doi.org/10.1111/j.1365-3156.2007.01995.x.
9. Briolant S, Henry M, Oeuvray C, Amalvict R, Baret E, Didillon E, Rogier C, Pradines B. 2010. Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother 54:3537-3544. http://dx.doi.org/10.1128/AAC.00183-10.
10. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A. 2009. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother 53:5069-5073. http://dx.doi.org/10.1128/AAC.00638-09.
11. Some AF, Sere YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouedraogo JB, Rosenthal PJ. 2010. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemetherlumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not di-hydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 54:1949-1954. http://dx.doi.org/10.1128/AAC.01413-09.
12. Some AF, Zongo I, Compaore YD, Sakande S, Nosten F, Ouedraogo JB, Rosenthal PJ. 2014. Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother 58:3660-3665. http://dx .doi.org/10.1128/AAC.02406-14.
13. Danquah I, Coulibaly B, Meissner P, Petruschke I, Muller O, Mockenhaupt FP. 2010. Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso. Acta Trop 114:63-66. http://dx.doi.org/10.1016/j.actatropica.2009.12.008.
14. Eastman RT, Dharia NV, Winzeler EA, Fidock DA. 2011. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother 55:3908-3916. http://dx.doi.org/10.1128/AAC.01793-10.
15. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. 2006. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother 50:1893-1895. http://dx .doi.org/10.1128/AAC.50.5.1893-1895.2006.
16. Ministry of Health of Burkina Faso. 2005. Application de la novelle politique de traitement du paludisme au Burkina Faso. No. 0932. Ministry of Health of Burkina Faso, Ougadougou, Burkina Faso.
17. Tinto H, Ouedraogo JB, Erhart A, Van Overmeir C, Dujardin JC, Van Marck E, Guiguemde TR, D'Alessandro U. 2003. Relationship between the Pfcrt T76 and the Pfmdr-1 Y86 mutations in Plasmodium falciparum and in vitro/in vivo chloroquine resistance in Burkina Faso, West Africa. Infect Genet Evol 3:287-292. http://dx.doi.org/10.1016/j.meegid.2003.08 .002.
18. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, Nambozi M, Valea I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D'Alessandro U. 2009. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoSOne 4:e7871. http://dx.doi.org /10.1371/journal.pone.0007871.
19. Paul RE, Packer MJ, Walmsley M, Lagog M, Ranford-Cartwright LC, Paru R, Day KP. 1995. Mating patterns in malaria parasite populations of Papua New Guinea. Science 269:1709-1711. http://dx.doi.org/10.1126 /science.7569897.
20. Muangnoicharoen S, Johnson DJ, Looareesuwan S, Krudsood S, Ward SA. 2009. Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob Agents Chemother 53:1362-1366. http://dx.doi.org/10.1128/AAC.01656-08.
21. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ. 2010. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother 54:1200-1206. http://dx.doi.org/10.1128/AAC.01412-09.
22. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. 2005. Piperaquine: a resurgent antimalarial drug. Drugs 65:75-87. http://dx.doi.org /10.2165/00003495-200565010-00004.
23. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H. 2008. Arte-mether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 3:e2390. http://dx.doi.org/10.1371/journal.pone.0002390.
24. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, Kamya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal PJ. 2014. Comparative impacts over 5 years of artemisininbased combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis 210:344-353. http://dx.doi.org/10.1093/infdis/jiu141.
25. Sisowath C, Petersen I, Veiga MI, Martensson A, Premji Z, Bjorkman A, Fidock DA, Gil JP. 2009. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis 199:750-757. http://dx.doi.org/10.1086/596738.
26. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP. 2005. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 191:1014-1017. http://dx.doi.org/10.1086/427997.
27. WHO. 2003. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria, vol WHO/HTM/ RBM/2003.5. World Health Organization, Geneva, Switzerland.